Skip to main content
Premium Trial:

Request an Annual Quote

Underwriters Partially Exercise Overallotment Option on Cancer Genetics' Public Offering

NEW YORK (GenomeWeb News) – Cancer Genetics today said that the underwriters for its recent public offering have partially exercised an overallotment option, purchasing an additional 105,000 shares at $10 per share.

As a result, the gross proceeds from the offering increased to about $16.1 million.

The Rutherford, NJ-based cancer diagnostics firm closed on the offering last month, and said that net proceeds would go toward expanding its sales and marketing operations; further commercializing products; investing in its joint venture with Mayo Clinic called OncoSpire; retiring mezzanine financing; and funding R&D and other general working capital needs.

Aegis Capital was the sole book-running manager for the offering, and Feltl and Co., was the co-lead manager. Cancer Genetics had granted the underwriters a 45-day option to purchase up to 225,000 additional shares of its common stock to cover any overallotments.

The Scan

Vaccine Update Recommended

A US Food and Drug Administration panel recommends booster vaccines be updated to target Omicron, CNBC reports.

US to Make More Vaccines for Monkeypox Available

The US is to make nearly 300,000 vaccine doses available in the coming weeks to stem the spread of human monkeypox virus, according to NPR.

Sentence Appealed

The Associated Press reports that Swedish prosecutors are appealing the sentence given to a surgeon once lauded for transplanting synthetic tracheas but then convicted of causing bodily harm.

Genome Biology Papers on COVID-19 Effector Genes, Virtual ChIP-seq, scDART

In Genome Biology this week: proposed COVID-19 effector genes, method to predict transcription factor binding patterns, and more.